These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 6416671

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nakahara memorial lecture. New classes of tumor promoters: teleocidin, aplysiatoxin, and palytoxin.
    Fujiki H, Suganuma M, Tahira T, Yoshioka A, Nakayasu M, Endo Y, Shudo K, Takayama S, Moore RE, Sugimura T.
    Princess Takamatsu Symp; 1983; 14():37-45. PubMed ID: 6151565
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Distinct inhibitory effects of dihydroteleocidin B and the phorbol ester tumor promoters on the adipocyte differentiation of 3T3-L1 cells.
    Shimizu Y, Shimizu N, Fujiki H, Sugimura T.
    Cancer Res; 1983 Oct; 43(10):4974-9. PubMed ID: 6192912
    [Abstract] [Full Text] [Related]

  • 5. Activation of protein kinase C and specific phosphorylation of a Mr 90,000 membrane protein of promotable BALB/3T3 and C3H/10T1/2 cells by tumor promoters.
    Chida K, Hashiba H, Sasaki K, Kuroki T.
    Cancer Res; 1986 Mar; 46(3):1055-62. PubMed ID: 3080229
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of tumor promoters on the frequency of metallothionein I gene amplification in cells exposed to cadmium.
    Hayashi K, Fujiki H, Sugimura T.
    Cancer Res; 1983 Nov; 43(11):5433-6. PubMed ID: 6616475
    [Abstract] [Full Text] [Related]

  • 8. Mitogenic and comitogenic properties of the indole alkaloid class of tumor promotors.
    Novogrodsky A, Patya M, Fujiki H, Rubin AL, Stenzel KH.
    J Cell Physiol; 1984 Jul; 120(1):36-40. PubMed ID: 6429160
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Activation of cytotoxic activity of human blood lymphocytes by tumor-promoting compounds.
    Ramos OF, Masucci MG, Klein E.
    Cancer Res; 1984 May; 44(5):1857-62. PubMed ID: 6201264
    [Abstract] [Full Text] [Related]

  • 18. [The actions of TPA-type as well as non-TPA type tumor promoters and their mechanism(s) in tumor promotion].
    Fujiki H.
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):758-65. PubMed ID: 2870684
    [Abstract] [Full Text] [Related]

  • 19. Absence of synergistic effects on tumor promotion in CD-1 mouse skin by simultaneous applications of two different types of tumor promoters, okadaic acid and teleocidin.
    Suganuma M, Yatsunami J, Yoshizawa S, Okabe S, Fujiki H.
    Cancer Res; 1993 Mar 01; 53(5):1012-6. PubMed ID: 8439947
    [Abstract] [Full Text] [Related]

  • 20. Promoter-induced cellular responses closely correlated with the enhancement of cell transformation.
    Kakunaga T, Hirakawa T, Shimomura K, Sugimura T.
    Princess Takamatsu Symp; 1983 Mar 01; 14():303-13. PubMed ID: 6097582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.